Celltrion Healthcare’s subcutaneous (SC) formulation of its infliximab biosimilar, codenamed CT-P13 SC, looks set to launch in Europe in the coming months in rheumatoid arthritis, after a p
The FDA has approved Pfizer’s biosimilar of AbbVie’s blockbuster Humira (adalimumab), meaning that there are now five of these cheaper near-copies teed up to compete when the originator’s p
Novartis’ biosimilars and generics division Sandoz has agreed to buy the Japanese business of the global generics firm Aspen in a deal worth up to 400 million euros ($434 million).
Biogen has gained rights to market two potential ophthalmology biosimilars in major markets including the US, Europe and Japan, under a new agreement signed with Samsung Bioepis.
A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.
